DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
530549 logo

Shilpa Medicare Limited Stock Price

BSE:530549 Community·₹188.1b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

530549 Share Price Performance

₹961.85
548.20 (132.53%)
​
₹603.00
Fair Value
₹961.85
548.20 (132.53%)
59.5% overvalued intrinsic discount
₹603.00
Fair Value
Price ₹961.85
AnalystConsensusTarget ₹603.00
AnalystHighTarget ₹1,200.00
AnalystLowTarget ₹481.00
Wed, 5 Aug 26
Fair Value₹603.00
Share Pricen/a

530549 Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value ₹603 59.5% overvalued intrinsic discount

530549: Global Expansion Will Accelerate With Upcoming Product Launches

0users have liked this narrative
1users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value ₹1.2k 19.8% undervalued intrinsic discount

Oncology Portfolios And Biosimilars Will Fuel Global Healthcare Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value ₹481 100.0% overvalued intrinsic discount

US And EU Regulatory Pressures Will Undermine Legacy Pipelines

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
530549 logo
Shilpa Medicare
19.8% undervalued intrinsic discount

Oncology Portfolios And Biosimilars Will Fuel Global Healthcare Expansion

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Sep
Read Narrative
530549 logo
Shilpa Medicare
59.5% overvalued intrinsic discount

530549: Global Expansion Will Accelerate With Upcoming Product Launches

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 5 Aug
Read Narrative
530549 logo
Shilpa Medicare
100.0% overvalued intrinsic discount

US And EU Regulatory Pressures Will Undermine Legacy Pipelines

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 21 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
530549 logo

530549: Higher Margins And Recall Management Will Support Stronger Future Outlook

Fair Value: ₹1.2k 19.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
530549 logo

530549: Dividend Plans And Office Shift Will Shape A Balanced Outlook

Fair Value: ₹603 59.5% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
530549 logo

530549: Upcoming Dividend And Office Shift Will Signal Limited Upside Potential

Fair Value: ₹481 100.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with high growth potential.

0 Risks
2 Rewards
View Full Analysis

Shilpa Medicare Limited Key Details

₹16.8b

Revenue

₹5.2b

Cost of Revenue

₹11.7b

Gross Profit

₹8.7b

Other Expenses

₹3.0b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
15.20
69.35%
17.66%
25.5%
View Full Analysis

About 530549

Founded
1987
Employees
1241
CEO
Vishnukant Bhutada
WebsiteView website
www.vbshilpa.com

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Recent 530549 News & Updates

User avatar
Narrative Update • Sep 03

530549: Higher Margins And Recall Management Will Support Stronger Future Outlook

Analysts have lifted their fair value estimate for Shilpa Medicare from ₹870 to ₹1,200, citing updates to revenue growth, profit margin and future P/E assumptions in their refreshed models. What’s in the News for Shilpa Medicare Shilpa Medicare initiated a voluntary Class II recall of PEMRYDI RTU (pemetrexed injection) 500 mg/50 mL in the US after market complaints of green to dark green discoloration in certain vials, affecting 9,489 vials across two lots, according to a US Food and Drug Administration enforcement report.
User avatar
Narrative Update • Aug 19

530549: Dividend Decision And Office Shift Will Shape Balanced Future Outlook

Analysts have lifted their fair value estimate for Shilpa Medicare from ₹748 to ₹870, citing updated assumptions for slightly higher revenue growth, profit margins, and a marginally lower future P/E multiple and discount rate. What's in the News for Shilpa Medicare Board meeting scheduled on 5 Aug 2026 to consider and approve unaudited financial results for the quarter ended 30 Jun 2026.

Recent updates

No updates

Shilpa Medicare Limited Competitors

SUNPHARMA logo

Sun Pharmaceutical Industries

Symbol: NSEI:SUNPHARMA
Market cap: ₹4.4t
DIVISLAB logo

Divi's Laboratories

Symbol: NSEI:DIVISLAB
Market cap: ₹2.5t
500420 logo

Torrent Pharmaceuticals

Symbol: BSE:500420
Market cap: ₹1.9t
ZYDUSLIFE logo

Zydus Lifesciences

Symbol: NSEI:ZYDUSLIFE
Market cap: ₹1.1t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide